BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9690661)

  • 1. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2.
    Diaz M; Abdul M; Hoosein N
    Prostate Suppl; 1998; 8():32-6. PubMed ID: 9690661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of chromogranins and regulation of their synthesis and processing in a neuroendocrine prostate tumor cell line.
    Ischia R; Culig Z; Eder U; Bartsch G; Winkler H; Fischer-Colbrie R; Klocker H
    Prostate Suppl; 1998; 8():80-7. PubMed ID: 9690667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
    Xie S; Lin HK; Ni J; Yang L; Wang L; di Sant'Agnese PA; Chang C
    Prostate; 2004 Jun; 60(1):61-7. PubMed ID: 15129430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
    Burchardt T; Burchardt M; Chen MW; Cao Y; de la Taille A; Shabsigh A; Hayek O; Dorai T; Buttyan R
    J Urol; 1999 Nov; 162(5):1800-5. PubMed ID: 10524938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
    Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
    Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of interleukin-8 expression in human prostate cancer cells by insulin-like growth factor-I and inflammatory cytokines.
    Kooijman R; Himpe E; Potikanond S; Coppens A
    Growth Horm IGF Res; 2007 Oct; 17(5):383-91. PubMed ID: 17513150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
    Yu DS; Hsieh DS; Chen HI; Chang SY
    J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine differentiation in prostate cancer.
    Shariff AH; Ather MH
    Urology; 2006 Jul; 68(1):2-8. PubMed ID: 16844446
    [No Abstract]   [Full Text] [Related]  

  • 13. Divergent neuroendocrine differentiation in prostatic carcinoma.
    di Sant' Agnese PA
    Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
    Cox ME; Deeble PD; Lakhani S; Parsons SJ
    Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interleukin-6 implication in prostate cancer].
    Cabrespine A; Bay JO; Verrelle P; Morel L
    Bull Cancer; 2007 Jul; 94(7 Suppl):F29-34. PubMed ID: 17845991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation.
    Wang Q; Horiatis D; Pinski J
    Prostate; 2004 Nov; 61(3):253-9. PubMed ID: 15368468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer.
    Wu C; Zhang L; Bourne PA; Reeder JE; di Sant'Agnese PA; Yao JL; Na Y; Huang J
    Prostate; 2006 Aug; 66(11):1125-35. PubMed ID: 16652382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
    Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
    Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
    Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
    Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo.
    Palmer J; Ernst M; Hammacher A; Hertzog PJ
    Prostate; 2005 Feb; 62(3):282-9. PubMed ID: 15389784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.